Additional file 3 of Comparative real-world study of apalutamide and darolutamide in Japanese patients with non-metastatic castration-resistant prostate cancer

Additional file 3. Studies on ARPIs in Japanese patients with nmCRPC. Abbreviations: n, number of cases; ARPI, androgen receptor pathway inhibitors; nmCRPC, nonmetastatic castration-resistant prostate cancer; MFS, metastasis-free survival; PSA, prostate-specific antigen; TRAEs, treatment-related adverse events; APA, apalutamide; DARO, darolutamide; ENZ, enzalutamide; ABI, abirateron acetate; OS, overall survival; PSADT, prostate-specific antigen doubling time; PSA at initiation, prostate-specific antigen level at treatment initiation; CRPC, castration-resistant prostate cancer; NR, not reached.附加文件3：日本非转移性去势抵抗性前列腺癌患者的雄激素受体通路抑制剂相关研究。缩略语说明：n：例数；ARPI：雄激素受体通路抑制剂（androgen receptor pathway inhibitors）；nmCRPC：非转移性去势抵抗性前列腺癌（nonmetastatic castration-resistant prostate cancer）；MFS：无转移生存期（metastasis-free survival）；PSA：前列腺特异性抗原（prostate-specific antigen）；TRAEs：治疗相关不良事件（treatment-related adverse events）；APA：阿帕他胺（apalutamide）；DARO：达罗他胺（darolutamide）；ENZ：恩扎卢胺（enzalutamide）；ABI：醋酸阿比特龙（abirateron acetate）；OS：总生存期（overall survival）；PSADT：前列腺特异性抗原倍增时间（prostate-specific antigen doubling time）；PSA at initiation：治疗起始时前列腺特异性抗原水平（prostate-specific antigen level at treatment initiation）；CRPC：去势抵抗性前列腺癌（castration-resistant prostate cancer）；NR：未达到（not reached）。